HUTCHMED files 6-K on SAFFRON phase III enrollment milestone

Rhea-AI Filing Summary

HUTCHMED (CHINA) LIMITED filed a Form 6-K furnishing Exhibit 99.1, a press release about completion of enrollment in the SAFFRON global phase III trial evaluating the combination of ORPATHYS and TAGRISSO for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.

Form 6-K: How Foreign Companies Report to the SEC →

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of November 2025

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.		Description
​	​	​
Exhibit 99.1	​	Press release relating to HUTCHMED announces enrollment completed of SAFFRON global phase III trial of ORPATHYS® and TAGRISSO® combination for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO®
​	​	​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: November 5, 2025

3

FAQ

What did HCM file?

HUTCHMED filed a Form 6-K furnishing a press release as Exhibit 99.1.

What is highlighted in the 6-K exhibit?

Exhibit 99.1 is a press release on completion of enrollment in the SAFFRON global phase III trial.

Which therapies are in the SAFFRON trial mentioned by HCM?

The trial evaluates a combination of ORPATHYS and TAGRISSO.

Which patients does the SAFFRON trial target?

Certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.

Which exhibit number contains the press release?

The press release is listed as Exhibit 99.1.

Does HCM file annual reports on Form 20-F or 40-F?

HUTCHMED files annual reports under cover of Form 20-F.

Who signed the submission for HCM?

It was signed by Johnny Cheng, Chief Financial Officer.